NGM(Delisted)
Ngm Biopharmaceuticals·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NGM
Ngm Biopharmaceuticals, Inc.
A company that developing therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases
333 Oyster Point Boulevard, South San Francisco, California 94080
--
Ngm Biopharmaceuticals, Inc., was incorporated in Delaware on December 20, 2007. The company is a biopharmaceutical company focused on the discovery and development of new, potentially life-changing drugs, based on a scientific understanding of the key biological pathways behind serious diseases with serious unmet or underserved patient needs. Since commencing operations in 2008, the company has produced a range of product candidates from early discovery to Phase 2b development. Currently, the company has five projects in clinical development.
Company Financials
EPS
NGM has released its 2023 Q4 earnings. EPS was reported at -0.33, versus the expected -0.39, beating expectations. The chart below visualizes how NGM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NGM has released its 2023 Q4 earnings report, with revenue of 165.00K, reflecting a YoY change of -99.09%, and net profit of -27.67M, showing a YoY change of 24.06%. The Sankey diagram below clearly presents NGM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
